All In Biotech

Drug Trial Radar · NCT06868732

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Evaluation of JSKN016 Combination Therapy in Subjects With Advanced Non-Small Cell Lung Cancer: A Phase Ib Study

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Apr 2, 2025

Primary completion

Jun 30, 2028

Study completion Dec 30, 2028

Sponsor

Sponsor type
Industry
First posted
Mar 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.

Conditions

  • Advanced Non-small Cell Lung Cancer

Interventions

  • JSKN016Drug

    Administered intravenously according to protocol.

  • CarboplatinDrug

    AUC 5, Q3W, administered intravenously according to protocol.

  • Furmonertinib MesylateDrug

    160mg(cohort1A-b)or 80mg(cohort 5), qd, administered according to protocol.

  • IvonescimabDrug

    20mg/kg, Q3W, administered intravenously according to protocol.

  • DocetaxelDrug

    60mg/m\^2, Q3W, administered intravenously according to protocol.

  • TislelizumabDrug

    200mg, Q3W, administered intravenously according to protocol.

  • PembrolizumabDrug

    200mg, Q3W, administered intravenously according to protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR assessed by the investigator per RECIST v1.1Time frame: Up to 24months
  2. Safety reflected by AETime frame: Up to 24months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.